Compare BridgeBio Pharma Inc (BBIO) vs Equinor ASA (EQNR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Equinor ASA — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Equinor ASA trades at $40.98 (market cap $95.91B). The key difference: Equinor ASA is far larger — about 5.8× BridgeBio Pharma Inc's market cap, and Equinor ASA pays a 3.81% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | EQNR | |
|---|---|---|
Market Cap | $16.61B | $95.91B |
Sector | Health | Energy |
52-Week High | $90.17 | $42.40 |
52-Week Low | $47.29 | $22.41 |
Enterprise Value | $18.16B | $104.60B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Equinor (EQNR) trades at $38.92, down 1.37% over the past day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 21.32% ROE and attractive valuation metrics, including a P/E of 10.55 and EV/EBITDA of 2.19. Recent Q2 2026 earnings missed estimates, but revenue grew 40% year-over-year, supported by higher energy prices and production. The company continues shareholder returns via dividends and a share buy-back program.
EQNR presents a mixed outlook: robust cash flow and strategic investments in subsea projects support growth, but declining net income margins and geopolitical energy market volatility pose risks. Analyst consensus is cautious with 30.43% buy ratings, reflecting fair valuation concerns after recent gains. The stock offers value through dividends and buybacks, yet investors face exposure to oil price swings and execution risks in capital projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →
